Decision Support Tool for HIV Treatment

HL
CT
Overseen ByChristian Takayama, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Keck School of Medicine of USC
Must be taking: Antiretroviral therapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new software tool, smART (Smart Antiretroviral Therapy Assistant), designed to help doctors select the best HIV treatments for their patients. HIV treatment can be complex due to factors like drug resistance and other health issues. The study aims to determine if this tool enables doctors to make better treatment choices more quickly and confidently. Individuals who might benefit from this trial include those with HIV who have undergone resistance testing for medications. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could simplify and enhance HIV treatment decisions.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop your current medications. It focuses on using a decision support tool to help providers choose HIV treatments.

What prior data suggests that this decision support tool is safe for use in HIV treatment?

Research has shown that the smART (Smart Antiretroviral Therapy Assistant) tool assists doctors in selecting the best HIV treatments for their patients. This tool offers recommendations based on guidelines to simplify treatment decisions. It is important to note that smART is not a medication or treatment but a digital tool for decision-making.

As a software tool, smART poses no direct safety concerns for patients. It does not interact with the body like a drug. Instead, it aids doctors in choosing the right HIV treatments, potentially leading to better patient outcomes. The goal is to simplify the process for healthcare providers, particularly those without easy access to HIV specialists.12345

Why are researchers excited about this trial?

Researchers are excited about the smART (Smart Antiretroviral Therapy Assistant) because it offers a new way to personalize HIV treatment. Unlike traditional online resources that provide general guidelines, smART is a digital tool that gives tailored, guideline-based recommendations specifically for each patient. This personalized approach could lead to more effective treatment plans and better patient outcomes. By integrating advanced decision-support technology, smART has the potential to streamline the decision-making process for healthcare providers, ultimately enhancing the quality of HIV care.

What evidence suggests that the smART tool is effective for HIV treatment?

Studies have shown that antiretroviral therapy (ART) helps people with HIV live longer and enjoy a better quality of life. It also reduces the risk of spreading HIV to others. This trial tests the smART tool, a digital clinical decision support tool, to assist doctors in selecting the best ART combinations for their patients. Although not yet fully tested in people, it aims to make treatment decisions quicker and more accurate by adhering to clinical guidelines. This tool could be particularly beneficial for doctors who do not specialize in HIV care, ensuring patients receive optimal treatment. Participants in this trial will use either the smART tool or traditional prescribing resources to guide their treatment decisions.16789

Who Is on the Research Team?

HL

Hayoun Lee, PhD

Principal Investigator

Keck School of Medicine of USC

Are You a Good Fit for This Trial?

This trial is for healthcare providers who prescribe HIV treatments. It aims to assist those who may not have specialist support in choosing the most effective antiretroviral therapy (ART) combinations for their patients with HIV/AIDS.

Inclusion Criteria

HIV patients with documented HIV-1 infection
HIV patients with genotype resistance testing previously conducted or scheduled through clinical care
My HIV treatment decisions are made by my care providers.
See 1 more

Exclusion Criteria

HIV patients with refusal or inability to give informed consent
HIV care providers with refusal to give informed consent

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Healthcare providers use patient cases to compare standard HIV treatment resources with a new clinical decision support tool

1 day per session
1 visit (in-person or virtual) per session

Follow-up

Participants are monitored for viral suppression rates and adherence to ART regimens

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • smART (Smart Antiretroviral Therapy Assistant)
Trial Overview The study compares a new software tool, smART, designed to provide evidence-based ART recommendations at the point of care, against traditional prescribing resources used by healthcare providers.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: smARTExperimental Treatment1 Intervention
Group II: Traditional Prescribing resourcesActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Keck School of Medicine of USC

Lead Sponsor

Trials
7
Recruited
1,000+

Los Angeles General Medical Center

Collaborator

Trials
1
Recruited
70+

AIDS Healthcare Foundation

Collaborator

Trials
19
Recruited
147,000+

Citations

Evaluating a Clinical Decision Support Tool for ...smART is a single-page, offline clinical decision support application that generates personalized HIV treatment recommendations by evaluating ...
Decision Support Tool for HIV Treatment · Info for ParticipantsThis study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients.
Major Clinical Outcomes in Antiretroviral Therapy (ART ...Abstract. BackgroundThe SMART study randomized 5472 human immunodeficiency virus (HIV)–infected patients with CD4+ cell counts >350 cells/μL to intermit.
A Systematic Review of Antiretroviral Adherence Interventions ...More conclusive data regarding the efficacy on cART adherence and HIV treatment outcomes using cognitive behavioral therapy, motivational interviewing, peer ...
Smartphone-based incentives for promoting adherence to ...Antiretroviral therapy (ART) increases life expectancy and quality of life for individuals infected with HIV, and can reduce the chance of HIV transmission ( ...
Ingestible Electronic Sensors for Monitoring Real-time ...Ingestible Electronic Sensors for Monitoring Real-time Adherence to HIV Pre-exposure Prophylaxis and Antiretroviral Therapy · Abstract.
Evaluating a Clinical Decision Support Tool for Antiretroviral ...This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients.
Guidelines for the Use of Antiretroviral Agents in Adults and ...Guidelines for the Use of Antiretroviral. Agents in Adults and Adolescents With HIV. Department of Health and Human Services. Available at https://clinicalinfo.
Guidelines for Using Antiretroviral Agents Among HIV ...Preliminary data indicate that treatment of primary HIV infection with combination therapy has a beneficial effect on laboratory markers of disease ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security